Cited 0 times in
Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정윤숙 | - |
dc.contributor.author | 천재희 | - |
dc.contributor.author | 홍성필 | - |
dc.contributor.author | 김원호 | - |
dc.contributor.author | 김태일 | - |
dc.date.accessioned | 2014-12-19T17:03:02Z | - |
dc.date.available | 2014-12-19T17:03:02Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0192-0790 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/90683 | - |
dc.description.abstract | BACKGROUND: Currently, 5-aminosalicylic acid (5-ASA)/sulfasalazine is used to empirically treat patients with intestinal Behcet disease (BD) without clear clinical evidence. In this study, we investigated long-term clinical outcomes and predictors of clinical relapse in patients with intestinal BD receiving 5-ASA/sulfasalazine maintenance therapy. METHODS: We reviewed the medical records of all the patients with intestinal BD, who received 5-ASA/sulfasalazine therapy in a single tertiary academic medical center between March 1986 and January 2011. The cumulative probabilities of clinical relapse after remission were calculated using the Kaplan-Meier method. Predictors of clinical relapse were identified by univariate analysis using the log-rank test and by multivariate analysis using Cox proportional hazards regression models. RESULTS: Among the 143 patients enrolled, 46 (32.2%) had a clinical relapse while they were being treated with 5-ASA/sulfasalazine therapy. The cumulative relapse rates at 1, 3, 5, and 10 years after remission were 8.1%, 22.6%, 31.2%, and 46.7%, respectively. By multivariate analysis, a younger age (<35 y) at the time of diagnosis, higher C-reactive protein level (≥1.5 mg/dL), and a higher disease activity index for intestinal Behcet disease score (≥60) at the time of 5-ASA/sulfasalazine initiation were independent predictors of relapse in patients with intestinal BD receiving 5-ASA/sulfasalazine maintenance therapy. CONCLUSIONS: This study has shown that 5-ASA/sulfasalazine therapy has a positive effect in maintaining remission in patients with intestinal BD. However, a younger age (<35 y), higher C-reactive protein level (≥1.5 mg/dL), and a higher disease activity index for intestinal Behcet disease score (≥60) were associated with a poor response to 5-ASA/sulfasalazine therapy, making careful observation and intensive treatment necessary in these risk groups. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | e38~e45 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL GASTROENTEROLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Anti-Inflammatory Agents, Non-Steroidal/therapeutic use* | - |
dc.subject.MESH | Behcet Syndrome/drug therapy* | - |
dc.subject.MESH | Behcet Syndrome/prevention & control | - |
dc.subject.MESH | C-Reactive Protein/analysis | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Intestinal Diseases/drug therapy* | - |
dc.subject.MESH | Intestinal Diseases/prevention & control | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Mesalamine/therapeutic use* | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Predictive Value of Tests | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Proportional Hazards Models | - |
dc.subject.MESH | Secondary Prevention | - |
dc.subject.MESH | Sulfasalazine/therapeutic use* | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Jung, Yoon Suk | - |
dc.contributor.googleauthor | Hong, Sung Pil | - |
dc.contributor.googleauthor | Kim, Tae Il | - |
dc.contributor.googleauthor | Kim, Won Ho | - |
dc.contributor.googleauthor | Cheon, Jae Hee | - |
dc.identifier.doi | 22298088 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03680 | - |
dc.contributor.localId | A04404 | - |
dc.contributor.localId | A00774 | - |
dc.contributor.localId | A01079 | - |
dc.contributor.localId | A04030 | - |
dc.relation.journalcode | J01319 | - |
dc.identifier.eissn | 1539-2031 | - |
dc.identifier.pmid | 22298088 | - |
dc.identifier.url | http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00004836-201205000-00002&LSLINK=80&D=ovft | - |
dc.subject.keyword | intestinal Behcet disease | - |
dc.subject.keyword | 5-aminosalicylic acid | - |
dc.subject.keyword | sulfa-salazine | - |
dc.subject.keyword | clinical relapse | - |
dc.contributor.alternativeName | Jung, Yoon Suk | - |
dc.contributor.alternativeName | Cheon, Jae Hee | - |
dc.contributor.alternativeName | Hong, Sung Pil | - |
dc.contributor.alternativeName | Kim, Won Ho | - |
dc.contributor.alternativeName | Kim, Tae Il | - |
dc.contributor.affiliatedAuthor | Jung, Yoon Suk | - |
dc.contributor.affiliatedAuthor | Hong, Sung Pil | - |
dc.contributor.affiliatedAuthor | Kim, Won Ho | - |
dc.contributor.affiliatedAuthor | Kim, Tae Il | - |
dc.contributor.affiliatedAuthor | Cheon, Jae Hee | - |
dc.citation.volume | 46 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 38 | - |
dc.citation.endPage | 45 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL GASTROENTEROLOGY, Vol.46(5) : 38-45, 2012 | - |
dc.identifier.rimsid | 33465 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.